AbbVie Inc. (ABBV) was up +3.36 percent to $106.95 as it met the quarterly revenue and income forecasts, and offered good guidance as well. The fourth-quarter net income posted by the biopharmaceutical company was $36 million, or 1 cent per share, compared to $2.8 billion and $1.88 per share a year ago.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Net earnings per share were $2.92, relative to the FactSet consensus of $2.85 and $2.21 a year ago. Compared to a forecast of $13.7 billion, sales rose 59 percent to $13.86 billion. Revenues from Humira rose 5 percent to $5.15 billion. For 2021, an adjusted EPS range from $ 12.32 to $ 12.52 is being considered by the company.
Boston Scientific Corporation (BSX) rose by +2.21% to $37.45. Lower-than-expected earnings and revenues were announced by the US medical technology giant. The company posted net profits of $138 million, or 10 cents per share, for the fiscal fourth quarter, compared to $4 billion and $2.83 per share a year ago.
Adjusted earnings per share are 23 cents, compared with 46 cents a year ago and 31 cents consensus, except products. Compared with analysts’ consensus estimate of $2.8 billion, sales plummeted 7 percent to $2.71 billion. The company predicts adjusted earnings per share of 28 to 34 cents for its first quarter, compared to a consensus of 35 cents. Revenues, opposed to a 7.6 percent consensus, are forecast to rise by 0 to 6 percent.
Humana Inc. (HUM) rose to $379.93, up +0.78 percent. A fourth-quarter GAAP loss per share of $2.07 and $2.3 on an adjusted basis was announced by the U.S. health insurer. At $2.36, the adjusted loss was projected to be much higher. Revenue remained equivalent to $19 billion and was beyond the forecasts of the industry.
The company also offers estimates for 2021 on earnings per share on a GAAP basis ranging from $20.82 to $21.32, while annual adjusted EPS is projected to be between $21.25 and $21.75.
